Low Dose Cyclophosphamide Treats Genital Warts

Status Completed

Clinical Trial Summary

Condylomata acuminata (CA) caused by human papillomavirus (HPV) is a common sexually transmitted disease with half a million new cases diagnosed in the United States per year. Recurrence is a major challenge for CA treatment. The investigators have demonstrated that FOXP3+ regulatory T (Treg) cells mediate the immunosuppression in large genital warts. And low-dose cyclophosphamide (CY), a conventional chemotherapy drug, has been reported to selectively deplete Treg cells in cancer patients. Therefore, the investigators hypothesized that low-dose CY can be used to treat genital warts. In this study, 104 CA patients have been recruited for clinical trial with a 1:2 randomization. Among them, 64 patients received low-dose cyclophosphamide and 32 received placebo. In 8 extra patients, high-dose cyclophosphamide was given.

Clinical Trial Description

Patients were first treated with CO2 laser therapy, and then treated with low-dose CY, orally 50 mg per day for 7 days.The CA recurrence were observed. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00999986
Study type	Interventional
Source	Huazhong University of Science and Technology
Contact
Status	Completed
Phase	Phase 3
Start date	January 2007
Completion date	August 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05518201` - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old	Phase 1
Completed	`NCT05372016` - Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	Phase 3
Recruiting	`NCT05027776` - Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years	Phase 3
Active, not recruiting	`NCT05580341` - Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9	Phase 3
Completed	`NCT03676101` - Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	Phase 1
Recruiting	`NCT04895020` - Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years	Phase 3
Completed	`NCT04425291` - Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	Phase 3
Recruiting	`NCT05371353` - Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Not yet recruiting	`NCT03153566` - Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients	Phase 3
Active, not recruiting	`NCT04073082` - Safety and Efficacy of Laser Therapy in Gynaecology
Terminated	`NCT05584332` - A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females	Phase 3
Completed	`NCT04796090` - Genital Wart and Sexuality in Adolescence
Enrolling by invitation	`NCT04905030` - Education, Immigration and HPV Vaccination: an Informational Randomized Trial	N/A
Recruiting	`NCT04422366` - Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	Phase 3